The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug ...

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with relapsed or refractory multiple myeloma.

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review additional materials submitted by the company, suggesting the company may ...

The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...

GSK’s blood cancer drug Blenrep has been reapproved by the EU medicines regulator after it was removed from sale in 2023 because a trial failed to show it was superior to other treatments.

Blenrep is a first-line inhibitor of BCMA, a cell-surface protein that plays a crucial role in the survival of plasma cells and is expressed on multiple myeloma cells Hot on the heels of US approval ...

The European Union has given regulatory approval to GSK's drug, Blenrep, for treating relapsed or treatment-resistant forms of blood plasma cell cancer.